HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $33 to $35.
September 08, 2023 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics' price target has been raised from $33 to $35 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Nurix Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100